6885.TWO
Price:
$37.6
Market Cap:
$4.93B
BRIM Biotechnology, Inc., a clinical-stage company, engages in the development of novel regenerative therapies to combat and cure ophthalmology and degenerative joint diseases. The company's lead product candidate is BRM 421, a topical ophthalmic solution for patients with moderate-to-severe dry eye syndrome that has completed a phase 2 clinical trial in the United States. It is also developing BRM 423 to treat severe corneal damage, which is in phase 1 clinical trial; BRM 424 for the treatment of neurotrophic keratitis, which is in phase 1 clinical trial; and BRM 521 to relieve and repair tissue damage caused by osteoarthritis. The company was founded in 2013 and is based in Taipei, Taiwan.
Industry
Biotechnology
IPO Date
2022-06-24
Stock Exchange
TWO
Ticker
6885.TWO
According to BRIM Biotechnology, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -7.77. This represents a change of -38.67% compared to the average of -12.67 of the last 4 quarters.
The mean historical PE Ratio of BRIM Biotechnology, Inc. over the last ten years is -11.26. The current -7.77 PE Ratio has changed 6.80% with respect to the historical average. Over the past ten years (40 quarters), 6885.TWO's PE Ratio was at its highest in in the December 2023 quarter at -1.49. The PE Ratio was at its lowest in in the June 2023 quarter at -29.99.
Average
-11.26
Median
-11.41
Minimum
-17.31
Maximum
-4.26
Discovering the peaks and valleys of BRIM Biotechnology, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 51.70%
Maximum Annual PE Ratio = -4.26
Minimum Annual Increase = -57.05%
Minimum Annual PE Ratio = -17.31
Year | PE Ratio | Change |
---|---|---|
2023 | -4.26 | -57.05% |
2022 | -9.92 | -26.02% |
2021 | -13.41 | -22.53% |
2020 | -17.31 | 51.70% |
The current PE Ratio of BRIM Biotechnology, Inc. (6885.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-9.19
5-year avg
-11.26
10-year avg
-11.26
BRIM Biotechnology, Inc.’s PE Ratio is
Company | PE Ratio | Market cap |
---|
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BRIM Biotechnology, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like BRIM Biotechnology, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is BRIM Biotechnology, Inc.'s PE Ratio?
How is the PE Ratio calculated for BRIM Biotechnology, Inc. (6885.TWO)?
What is the highest PE Ratio for BRIM Biotechnology, Inc. (6885.TWO)?
What is the 3-year average PE Ratio for BRIM Biotechnology, Inc. (6885.TWO)?
What is the 5-year average PE Ratio for BRIM Biotechnology, Inc. (6885.TWO)?
How does the current PE Ratio for BRIM Biotechnology, Inc. (6885.TWO) compare to its historical average?